Cargando…

Altered glycosylation in pancreatic cancer and beyond

Pancreatic ductal adenocarcinoma (PDA) is one of the deadliest cancers and is projected to soon be the second leading cause of cancer death. Median survival of PDA patients is 6–10 mo, with the majority of diagnoses occurring at later, metastatic stages that are refractory to treatment and accompani...

Descripción completa

Detalles Bibliográficos
Autores principales: Lumibao, Jan C., Tremblay, Jacob R., Hsu, Jasper, Engle, Dannielle D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rockefeller University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9086500/
https://www.ncbi.nlm.nih.gov/pubmed/35522218
http://dx.doi.org/10.1084/jem.20211505
_version_ 1784704016130768896
author Lumibao, Jan C.
Tremblay, Jacob R.
Hsu, Jasper
Engle, Dannielle D.
author_facet Lumibao, Jan C.
Tremblay, Jacob R.
Hsu, Jasper
Engle, Dannielle D.
author_sort Lumibao, Jan C.
collection PubMed
description Pancreatic ductal adenocarcinoma (PDA) is one of the deadliest cancers and is projected to soon be the second leading cause of cancer death. Median survival of PDA patients is 6–10 mo, with the majority of diagnoses occurring at later, metastatic stages that are refractory to treatment and accompanied by worsening prognoses. Glycosylation is one of the most common types of post-translational modifications. The complex landscape of glycosylation produces an extensive repertoire of glycan moieties, glycoproteins, and glycolipids, thus adding a dynamic and tunable level of intra- and intercellular signaling regulation. Aberrant glycosylation is a feature of cancer progression and influences a broad range of signaling pathways to promote disease onset and progression. However, despite being so common, the functional consequences of altered glycosylation and their potential as therapeutic targets remain poorly understood and vastly understudied in the context of PDA. In this review, the functionality of glycans as they contribute to hallmarks of PDA are highlighted as active regulators of disease onset, tumor progression, metastatic capability, therapeutic resistance, and remodeling of the tumor immune microenvironment. A deeper understanding of the functional consequences of altered glycosylation will facilitate future hypothesis-driven studies and identify novel therapeutic strategies in PDA.
format Online
Article
Text
id pubmed-9086500
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-90865002022-05-23 Altered glycosylation in pancreatic cancer and beyond Lumibao, Jan C. Tremblay, Jacob R. Hsu, Jasper Engle, Dannielle D. J Exp Med Review Pancreatic ductal adenocarcinoma (PDA) is one of the deadliest cancers and is projected to soon be the second leading cause of cancer death. Median survival of PDA patients is 6–10 mo, with the majority of diagnoses occurring at later, metastatic stages that are refractory to treatment and accompanied by worsening prognoses. Glycosylation is one of the most common types of post-translational modifications. The complex landscape of glycosylation produces an extensive repertoire of glycan moieties, glycoproteins, and glycolipids, thus adding a dynamic and tunable level of intra- and intercellular signaling regulation. Aberrant glycosylation is a feature of cancer progression and influences a broad range of signaling pathways to promote disease onset and progression. However, despite being so common, the functional consequences of altered glycosylation and their potential as therapeutic targets remain poorly understood and vastly understudied in the context of PDA. In this review, the functionality of glycans as they contribute to hallmarks of PDA are highlighted as active regulators of disease onset, tumor progression, metastatic capability, therapeutic resistance, and remodeling of the tumor immune microenvironment. A deeper understanding of the functional consequences of altered glycosylation will facilitate future hypothesis-driven studies and identify novel therapeutic strategies in PDA. Rockefeller University Press 2022-05-06 /pmc/articles/PMC9086500/ /pubmed/35522218 http://dx.doi.org/10.1084/jem.20211505 Text en © 2022 Lumibao et al. https://creativecommons.org/licenses/by/4.0/This article is available under a Creative Commons License (Attribution 4.0 International, as described at https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Lumibao, Jan C.
Tremblay, Jacob R.
Hsu, Jasper
Engle, Dannielle D.
Altered glycosylation in pancreatic cancer and beyond
title Altered glycosylation in pancreatic cancer and beyond
title_full Altered glycosylation in pancreatic cancer and beyond
title_fullStr Altered glycosylation in pancreatic cancer and beyond
title_full_unstemmed Altered glycosylation in pancreatic cancer and beyond
title_short Altered glycosylation in pancreatic cancer and beyond
title_sort altered glycosylation in pancreatic cancer and beyond
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9086500/
https://www.ncbi.nlm.nih.gov/pubmed/35522218
http://dx.doi.org/10.1084/jem.20211505
work_keys_str_mv AT lumibaojanc alteredglycosylationinpancreaticcancerandbeyond
AT tremblayjacobr alteredglycosylationinpancreaticcancerandbeyond
AT hsujasper alteredglycosylationinpancreaticcancerandbeyond
AT engledannielled alteredglycosylationinpancreaticcancerandbeyond